The metal sector, a cornerstone of industrial growth, has been exhibiting strong performance across various key minerals and non-ferrous metals. As we look into February 2025, the industry continues to benefit from robust demand across diverse sectors like infrastructure, energy, automotive, and construction.

The Ministry of Mines reported impressive production figures for FY 2024-25, with iron ore production increasing by 5.5% to 135 million metric tonnes (MMT) from the previous year. This growth comes after record production in FY 2023-24, reflecting strong demand in the steel industry, one of the largest consumers of iron ore.

Similarly, manganese ore production rose by 6.2%, and primary aluminium production grew by 1.2%, marking a positive trend in the non-ferrous metal sector. Moreover, India remains the second-largest producer of aluminium, one of the top-10 producers of refined copper, and the fourth-largest iron ore producer in the world.

In this context, let’s take a look at the top metal sector stocks based on their 5-year CAGR performance.

Top Metal Sector Stocks in February 2025

Note: The best metal sector stocks list provided here is as of February 03, 2025. The stocks are sorted as per their 5-year CAGR.

Overview of the 5 Best Metal Stocks in India

1. Jindal Stainless Ltd

Jindal Stainless is India’s leading stainless steel manufacturer with a consolidated annual turnover of ₹38,562 crore (USD 4.7 billion) in FY24. The company operates 16 stainless steel manufacturing and processing facilities across India and globally, with a focus on sustainability and innovation, aiming to achieve Net Zero by 2050.

In Q3 FY25, Jindal Stainless reported a 5.4% year-on-year decline in net profit, which stood at ₹654.84 crore. However, the company saw an 8.5% increase in revenue from operations, reaching ₹9,907.30 crore, driven by a 15% growth in sales volume despite challenges in the export market.

Key metrics:

• ROCE: 20.01%
• ROE: 20.06%

 

2. National Aluminium Co Ltd

National Aluminium Company Limited (NALCO) is a leading Navratna public sector enterprise in India, founded in 1981. NALCO operates one of the country’s largest integrated bauxite, alumina, and aluminium production facilities, contributing significantly to the Indian aluminium industry.

In Q3 FY23, NALCO reported a 61% sequential increase in net profit, reaching ₹274 crore, compared to ₹170 crore in the previous quarter. The company’s net sales turnover for the quarter was ₹3,290 crore, driven by higher production volumes and global aluminium price improvements.

Key metrics:

• ROCE: 17%
• ROE: 14.45%

 

3. Jindal Steel & Power

Jindal Steel & Power (JSP) is a leading Indian conglomerate with a strong presence in steel, mining, power, and infrastructure sectors. Operating across India, Africa, and Australia, JSP has emerged as a global leader in its industries, driven by innovation and a commitment to the vision of Make in India.

For Q3FY25, JSP’s net profit declined to ₹950.88 crore, a significant decrease from ₹1,927.99 crore in the same quarter last year. Revenue remained almost flat at ₹11,750.67 crore, reflecting modest growth in steel sales despite challenging market conditions.

Key metrics:

• ROCE: 12.02%
• ROE: 14.18%

 

4. JSW Steel Ltd

JSW Steel, the flagship company of the diversified JSW Group, is one of India’s leading steel manufacturers, with a capacity of 35.7 MTPA across India and the USA. The company is known for its excellence in steel production, innovation, and sustainability practices.

In Q3 FY25, JSW Steel reported a 70.3% decline in consolidated net profit, falling to ₹717 crore, driven by lower steel prices. Total revenues for the quarter stood at ₹41,378 crore, showing a marginal 1.3% year-on-year decline.

Key metrics:

• ROCE: 13.28%
• ROE: 12%

 

5. Vedanta Ltd

Vedanta Limited, a leading global natural resources conglomerate, operates in sectors like aluminium, zinc-lead-silver, oil and gas, iron ore, steel, copper, power, ferro alloys, and more. With assets across India, South Africa, Namibia, and Liberia, Vedanta focuses on sustainability, growth, and long-term value creation.

In Q3 FY25, Vedanta reported a 76.2% increase in net profit, reaching ₹3,547 crore. This surge was attributed to improved operational efficiencies, robust cash flows, and favourable market conditions.

Key metrics:

• ROCE: 27.25%
• ROE: 9.27%

 

Debt-to-Equity Ratios of Top Metal Sector Companies

 

Sub-Sectors of Top Metal Companies

Conclusion

The metal sector in India remains a strong pillar of industrial growth, driven by robust demand in key industries such as infrastructure, energy, automotive, and construction. While the market conditions may vary and challenges persist, these companies continue to show promising 5-year CAGR performance, signalling their ability to adapt and thrive.

Investors looking to capitalise on the metal sector should carefully consider the financial health, growth potential, and risks associated with each company. As always, it’s important to conduct thorough research or consult with a financial advisor before making investment decisions, ensuring they align with individual financial goals and risk tolerance.

 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

On February 3, 2025, the Indian stock market benchmark index BSE and the Nifty closed in the red. The BSE Sensex was down by 0.41% closing at 77,186.74, while the Nifty50 was down by 0.52% at 23,361.05. Among sectors, the Nifty Metal and Nifty FMCG witnessed a more than 1.5% decline.

Top Gainers of the Day

• Bajaj Finance Limited

Bajaj Finance Limited reached a high of ₹8,439.30 and closed at ₹8,410, reflecting a 5.12% increase.

• Shriram Finance Limited

Shriram Finance touched a high of ₹558 and ended at ₹548.05, marking a 3.06% rise.

• Mahindra & Mahindra Limited

Mahindra & Mahindra’s share price peaked at ₹3,187.95, closing at ₹3,169, up by 3%.In January 2025, Mahindra experienced a 16% growth in total sales, driven mainly by robust SUV sales, a notable increase in exports, and a strong focus on expanding its electric vehicle offerings.

• Wipro Limited

Wipro’s stock hit a high of ₹314 and finished at ₹313.10, with a 2.72% increase.

• Bajaj Finserv Limited

Bajaj Finserv’s share price reached a high of ₹1,805 and closed at ₹1,794.75, gaining 2.32%.

Top Losers of the Day

• Larsen & Toubro Limited

L&T’s stock recorded a low of ₹3,270, closing at ₹3,285.95, showing a decrease of 4.69%.

• Tata Consumer Products Limited

Tata Consumer Products Limited’s stock reached a low of ₹1,033.65, closing at ₹1,037, down by 3.07%.

• Hero MotoCorp Limited

Hero MotoCorp’s stock peaked at ₹4,430 and ended at ₹4,270.80, reflecting a decrease of 2.98%. Hero MotoCorp saw a 2.14% rise in total sales, reaching 442,873 units in January 2025, up from 433,598 units in the same month of 2024.

• Coal India Limited

Coal India’s stock saw a low of ₹366.50, closing at ₹374.20, down by 2.88%. Coal India’s production in January 2025 was 77.8 million tonnes (mt), marking a 0.8% decrease compared to 78.4 mt in January 2024.

• Bharat Electronics Limited

BEL’s stock hit a low of ₹263.30, closing at ₹273.80, down by 2.84%.

 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Shares of Coal India declined for the second consecutive day due to concerns over its ability to meet the FY25 production target of 838 MT. The company’s production is lagging, and a 37% increase is needed in Q4.

Coal India’s Subsidiaries Underperform

As of January, Coal India had produced 621.1 MT of coal, 1.8% higher than the same period last year, but still only 74.1% of the annual target. To meet the target, production must increase by 37% in the final quarter of FY25. As per news reports five of Coal India’s subsidiaries have missed their production targets for the first nine months of FY25.

Coal India’s January Production Declines 

Coal India Ltd (CIL) reported a 0.8% year-on-year decline in its coal production for January, with output falling to 77.8 million tonnes (MT) from 78.4 MT in the same month last year. This marks the company’s first monthly production drop.

Despite this, CIL remains optimistic about a strong recovery in the final quarter of FY25.

The company’s output growth from April 2024 to January 2025 stands at 1.8%, reaching 621.1 MT compared to 610.3 MT in the same period last year. CIL’s coal offtake in January increased by 2.2% to 68.6 MT from 67.1 MT year-on-year, and for the fiscal year-to-date, it has seen a 1.8% rise in offtake, totalling 630.2 MT.

The primary contributors to the production decline in January were South Eastern Coalfields Ltd (SECL) and Bharat Coking Coal Ltd (BCCL), with SECL’s output falling by 11.8% to 17.4 MT from 19.7 MT in January 2024.

Share Price Performance

As of February 3, 2025, Coal India Ltd (CIL) experienced a significant decline in its share price, dropping by ₹12.00 or 3.11%, closing at ₹373.30 compared to ₹385.30 the previous day. During the day, the stock traded between ₹366.50 and ₹384.15, with an indicative close of ₹371.74. This decline follows a 2.7% drop in the previous session.

 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

K.P. Energy sees a 5-day share price rise after successfully commissioning 25.8 MW of a 28.6 MW wind power project in Bharuch. The company’s total renewable energy capacity now stands at 45.7 MW, the company said in a press release on the stock exchanges.

Continued Growth in IPP Capacity

The company has successfully commissioned 25.8 MW out of the total 28.6 MW capacity at its wind power project located at the Vagra site in Bharuch. This achievement represents significant progress in the company’s renewable energy portfolio.

With the completion of this project, K.P. Energy’s total independent power producer (IPP) capacity now stands at 45.7 MW. The company is also working on commissioning the remaining 2.8 MW capacity by the end of this month.

Share Price Performance

K.P. Energy Limited’s share price is currently trading at ₹419.95, showing an increase of ₹5.20, or 1.25%, from its previous close of ₹414.75. The stock opened at ₹413.00 and reached a high of ₹435.45, with a low of ₹404.50 during the session. The stock price has gained close to 20% in recent sessions.

Recent Development

Last month, K.P. Energy successfully commissioned a 6.3 MW (Phase-XI) ISTS-connected Wind Power Project at the Sidhpur site in Devbhoomi Dwarka.

This project, comprising three 2.1 MW wind turbine generators (WTGs), is part of the 250.8 MW wind power project awarded to Apraava Energy Private Limited by Solar Energy Corporation of India (SECI).

With the commissioning of Phase-XI, the total commissioned capacity at the Sidhpur site stands at 252 MW, exceeding the originally awarded capacity of 250.8 MW.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Sun Pharmaceutical’s share price traded at ₹1,738.35 at 10:50 AM on the NSE, showing a marginal decline of ₹3.85 or 0.22% from its previous close of ₹1,742.20. The stock opened higher at ₹1,781.45 and reached a high of ₹1,785.90 during the session. However, it experienced a pullback, dipping to a low of ₹1,734.75.

Sun Pharma Q3 Results: Strong Performance

Sun Pharmaceutical Industries posted strong results for Q3 FY25. Despite this, there are concerns about the delayed launch of its hair loss drug, Leqselvi, and a reduction in research and development (R&D) spending.

The company has revised its FY25 R&D guidance to below 7% of sales, citing delays in clinical trials. While this adjustment is expected to improve short-term earnings, it may affect the company’s long-term product pipeline.

Leqselvi Launch Faces Uncertainty

A significant concern for Sun Pharma is the postponed launch of Leqselvi, a specialty treatment for hair loss. The company has indicated that oral arguments in the ongoing patent case are scheduled for April 2025.

Should the ruling be unfavourable, the launch could be pushed back to December 2026, when the patent expires. This delay is becoming a growing issue, despite the specialty business’s overall solid performance.

Sun Pharma Acquires Antibe Therapeutics

Sun Pharmaceutical Industries entered into a definitive agreement to acquire 100% shares of Antibe Therapeutics Inc., a clinical-stage biotechnology firm based in Ontario, Canada.

Antibe, which primarily focuses on developing drugs to alleviate pain and inflammation, is currently under court-managed liquidation. The acquisition will take place under a reverse Vesting Order, with certain assets and liabilities being transferred to a residual company before closing.

The deal, which requires approval from the Ontario Superior Court of Justice, is expected to be completed by March 7, 2025. As of now, the financial details of the transaction, including the acquisition cost, are undisclosed and will be revealed once finalised.

 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Aarti Industries’ share price is currently at ₹453, marking a decline of ₹6.65 (1.45%) from the previous close of ₹459.65. The stock had gained over 11% in the last four trading sessions. It opened at ₹445.05, hit a high of ₹460.80, and a low of ₹428.50 during today’s session.

Aarti Industries Q3 FY25

Aarti Industries reported a significant 63% year-on-year drop in its net profit, which stood at ₹46 crore for Q3 FY25, compared to ₹124 crore in the previous year. This decline was primarily attributed to higher finance costs and increased expenses.

Despite the drop in profit, the company’s revenue for the quarter showed a positive growth of 6%, rising to ₹1,840 crore from ₹1,732 crore in the same quarter last year. However, EBITDA decreased by 11.2% year-on-year to ₹231 crore, reflecting pressure on margins which fell from 15% to 12.6%.

Outlook and Future Plans

Aarti Industries highlighted strong volume growth and improved product mix as key contributors to its performance despite market challenges. Exports saw sequential growth, while domestic volumes remained stable across most applications.

CEO and Executive Director, Suyog Kotecha, expressed confidence in the company’s position moving forward, emphasising risk mitigation through cost efficiencies, product diversification, and expansion into high-growth global markets including the US, Europe, and Japan.

The company remains focused on its innovation pipeline and sustainability efforts to capitalise on future opportunities.

Aarti Industries Enters Renewable Energy Sector

In January, Aarti Industries entered into a “Share Subscription and Shareholder’s Agreement” with Prozeal Green Power Private Limited and Pro-Zeal Green Power Seven Private Limited.

The agreement involved the acquisition of 26.25% equity shares and compulsory convertible debentures (CCDs) in Pro-Zeal Green Power Seven Private Limited, an SPV for developing a 9.24 MW solar power plant to meet part of Aarti Industries’ power requirements.

This move aligns with the company’s strategy to source power from renewable energy and reduce overall power costs. The plant is expected to start generating power by H2 FY26. The investment includes ₹6.3 lakh in equity and ₹3.63 crore in CCDs, the company said in a press release on the stock exchanges.

 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Lupin announced that its Somerset, New Jersey facility successfully completed a USFDA Pre-Approval Inspection for Edaravone Oral Suspension with zero 483 observations, demonstrating the company’s commitment to high-quality standards, the company said in a press release on the stock exchanges.

Overview of Successful U.S. FDA Pre-Approval Inspection

The inspection, which took place from January 28 to February 1, 2025, at Lupin’s manufacturing facility in Somerset, New Jersey, concluded with zero 483 observations, affirming the company’s high standards of quality and compliance.

Lupin Limited, a global leader in the pharmaceutical industry, has announced the successful completion of a Pre-Approval Inspection (PAI) by the U.S. Food and Drug Administration (FDA) for its Edaravone Oral Suspension, 105 mg/5 mL.

Lupin’s Commitment to Quality

In a statement, Nilesh Gupta, Managing Director of Lupin, expressed his satisfaction with the inspection’s outcome, stating, “The successful outcome of the US FDA inspection at our Somerset facility is a testament to our commitment to uphold and maintain the highest standards of quality, compliance, and safety across our facilities. We remain steadfast in our mission to improve the lives of our patients globally.”

This achievement highlights Lupin’s dedication to ensuring its manufacturing processes meet stringent regulatory standards, reflecting the company’s ongoing efforts to maintain and enhance the quality of its products across various therapeutic areas.

About Lupin

Lupin is a prominent global pharmaceutical company headquartered in Mumbai, India, and is known for its wide range of products, including branded and generic formulations, biotechnology products, and active pharmaceutical ingredients. With a strong presence in over 100 markets, Lupin has 15 state-of-the-art manufacturing sites and 7 research centres worldwide.

Share Price Performance

As of February 3, 2025, Lupin Limited’s share price traded at ₹2,016.80 at 10:00 AM on the NSE, reflecting a decline of ₹39.45 or -1.92% from the previous closing price of ₹2,056.25. The stock opened at ₹2,056.25 and reached a high of ₹2,074.90 and a low of ₹2,006.25 during the trading session.

 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.